(Q33980711)

English

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults (English)

1 reference

Europe PubMed Central

30 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

8

object named as

M S Saag

1 reference

Europe PubMed Central

30 July 2017

author name string

J M Kilby

1

1 reference

Europe PubMed Central

30 July 2017

G Sfakianos

2

1 reference

Europe PubMed Central

30 July 2017

N Gizzi

3

1 reference

Europe PubMed Central

30 July 2017

P Siemon-Hryczyk

4

1 reference

Europe PubMed Central

30 July 2017

E Ehrensing

5

1 reference

Europe PubMed Central

30 July 2017

C Oo

6

1 reference

Europe PubMed Central

30 July 2017

N Buss

7

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

30 July 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

30 July 2017

44

1 reference

Europe PubMed Central

30 July 2017

10

1 reference

Europe PubMed Central

30 July 2017

2672-2678

1 reference

Europe PubMed Central

30 July 2017

Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

HIV-protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

How often is medication taken as prescribed? A novel assessment technique

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

28 July 2018

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90133

29 October 2018

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10991842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.44.10.2672-2678.2000

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33980711&oldid=1984495595"